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Abstract
The article by Eslami and colleagues provides an overview of the
indicators used to measure the quality of blood glucose control in
patients admitted to the intensive care unit. Each indicator can be
related to one or more of the following categories: blood glucose
zones, blood glucose levels, time intervals, and features of the
insulin titration algorithm. Some important issues (for instance
those concerning the clarity of definitions used for glycaemic
thresholds) are raised. This systematic review calls for a practical
guide to advise the clinician how different blood glucose signals
should (ideally) be evaluated and which steps should to be
undertaken.
In the previous issue of Critical Care, Eslami and coworkers
[1] review the various outcome measures used to evaluate
the quality of blood glucose (BG) control (level of ‘tight
glycaemic control’ [TGC]) in critically ill patients; the review
considers studies published prior to 2008. We should like to
congratulate the authors for their careful search and analysis.
They subdivided 30 different indicators into four nonortho-
gonal categories: BG zones (adverse zones versus in-range
zones), BG levels (for example, mean BG), time intervals (for
example, time within a predefined BG range), and protocol
features (for example, BG sampling frequency).
In recent years, the definition of TGC had appeared to be
well established, based on the findings of two randomized
controlled clinical trials that clearly demonstrated the relation
between strictly regulated BG (80 to 110 mg/dl) and reduc-
tion in mortality/morbidity [2,3]. More recently, however, the
level of TGC has emerged as a controversial issue, following
publication of the findings of two other (under-powered)
clinical trials that were unsuccessful in implementing TGC
into daily practice [4,5]. Control of BG to achieve a clinically
and ethically approved target remains a crucial element in the
treatment of intensive care unit (ICU) patients and necessi-
tates the design and assessment of measures that reflect this
level of control. The paper by Eslami and coworkers presents
an overview of existing indicators, but rigorous assessment to
identify the optimal indicator(s) is now required.
Two important facts (already partly discussed by Eslami and
coworkers [1]) must be emphasized. First, there is no con-
sensual definition of some methodologies that are currently
used as an indicator. Take the definition for ‘hypoglycaemia’
as an example. Eslami and coworkers identified 15 different
thresholds for BG, varying from <40 mg/dl to <72 mg/dl. In
some studies any measurement below the threshold is
regarded ‘hypoglycaemia’, whereas other studies take the
time dimension into account in order to ensure that multiple
hypoglycaemic events occurring over a short interval (for
example, 30 minutes) are evaluated as a single event. In still
other studies, definitions are not explained, which hampers
comparison between different levels of glucose control.
Second, the availability of a near-continuous glucose sensor
is a prerequisite for reliable TGC assessment, but no near-
continuous glucose sensor has yet been found to be
sufficiently reliable and accurate for use in critically ill
patients. Accordingly, only time-discrete measurements of
glycaemia (for instance, a time interval of 1 hour or more) are
available, which can be dealt with in two ways. On the one
hand, the time dimension can be neglected such that only the
effectively measured values are considered in the analysis (for
example, mean BG, Glycaemic Penalty Index (GPI) [6], and
so on). As Eslami and coworkers correctly point out, this type
of analysis may be sensitive to sampling. On the other hand,
nonmeasured values can be estimated, leading to a (non-
measured) continuous glucose signal, allowing application of
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area under the curve indicators (for example, Hyperglycaemic
Index [HGI] [7]). Here, however, a typically linear relation
between observations is assumed (in order to achieve an
approximation to the true, nonlinear dynamics of BG
fluctuation), which explains why this second technique can
lead to incorrect assessment of BG signals.
Ideally, adequate assessment of a BG signal and comparison
with other BG signals require the fulfilment of three condi-
tions. The first of these is consensus concerning the desired
target BG range (and definitions of hypoglycaemia/hyper-
glycemia). The two landmark studies [2,3] and a new clinical
trial [8] have shown that achieving age-adjusted strict
normoglycaemia throughout the ICU stay leads to lower ICU
mortality and morbidity, in both adult and paediatric ICU
patients. Second, the use of future reliable near-continuous
glucose sensors will permit appropriate consideration of the
time dimension in the indicator. Accordingly, duration and
magnitude of hypoglycaemic/hyperglycemic events are repre-
sented more precisely, as compared with time-discrete BG
signals. Third, clinicians must be aware that traditional
measures (for instance, mean BG) potentially can confound
evaluation, as previously discussed [6].
More advanced indicators such as HGI and GPI (note that
GPI, introduced in 2008 [6], was not evaluated by Eslami and
coworkers [1]) are indispensable for adequate assessment of
the overall level of BG control and are less complex than is
sometimes claimed. Indeed, the HGI (and, analogously, the
Hypoglycaemic Index [9]) and GPI combine the first three
categories mentioned by Eslami and coworkers [1]: BG
zones, BG levels and time intervals. While we await the
availability of near-continuous glucose monitoring devices, we
advise clinicians to compute both HGI and GPI (per patient),
because these indicators compensate for each other’s
weaknesses. Next, population HGI and GPI values can be
obtained by computing the median and 25% to 75%
interquartile range, because most BG distributions are non-
normal. Finally, it is important to note (particularly when
comparing different BG signals) the impact that study design
(BG sampling frequency and duration of algorithm
application) has on the level of BG control [6].
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